Last reviewed 2026-05-30 · How we verify

Fine Concentrated Ambient Particles

University of California, Los Angeles · Phase 1 active Small molecule ✓ Verified May 2026 Quality 0/100

Fine Concentrated Ambient Particles is a Small molecule drug developed by University of California, Los Angeles. It is currently in Phase 1 development.

Fine Concentrated Ambient Particles have been studied in relation to conditions such as air pollution, hypersensitivity, and atopic hypersensitivity. The studies involved exposing healthy young volunteers to PM exposure, filtered air exposure, and carbon black to investigate the health effects of repeated exposure to low levels of concentrated ambient particles.

Likelihood of approval

9.6% vs 9.6% industry baseline

If approved by FDA: likely 2033–2036

Steps remaining: Phase 2 → Phase 3 → NDA/BLA submission

Confidence: Medium

Why this estimate

Baseline phase 1 → approval rate +9.6pp
Industry-wide phase 1 drugs reach approval ~9.6% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).

Predicted approval windows by jurisdiction (conditional on FDA approval)

Regulator	Country	Likely year	Lag vs FDA
FDA	US	2033–2036	—
EMA	EU	2034–2037	+0.7 yr
MHRA	GB	2034–2037	+0.7 yr
Health Canada	CA	2034–2038	+0.9 yr
TGA	AU	2034–2038	+1.2 yr
PMDA	JP	2034–2038	+1.5 yr
NMPA	CN	2035–2039	+2.3 yr
MFDS	KR	2034–2038	+1.4 yr
CDSCO	IN	2034–2039	+1.8 yr
ANVISA	BR	2035–2039	+2.3 yr

Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).

Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.

At a glance

Generic name	Fine Concentrated Ambient Particles
Sponsor	University of California, Los Angeles
Modality	Small molecule
Phase	Phase 1

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Fine Concentrated Ambient Particles CI brief — competitive landscape report
Fine Concentrated Ambient Particles updates RSS · CI watch RSS
University of California, Los Angeles portfolio CI

Frequently asked questions about Fine Concentrated Ambient Particles

What is Fine Concentrated Ambient Particles?

Fine Concentrated Ambient Particles is a Small molecule drug developed by University of California, Los Angeles.

Who makes Fine Concentrated Ambient Particles?

Fine Concentrated Ambient Particles is developed by University of California, Los Angeles (see full University of California, Los Angeles pipeline at /company/university-of-california-los-angeles).

What development phase is Fine Concentrated Ambient Particles in?

Fine Concentrated Ambient Particles is in Phase 1.

Manufacturer: University of California, Los Angeles — full pipeline

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing